WINDTREE THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1992-11-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.windtreetx.com
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT05975021
- Locations
- 🇮🇱
Kaplan Medical Center, Reẖovot, Israel
🇺🇸Oregon Health and Sciences University, Portland, Oregon, United States
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
- Conditions
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)COVID-19
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04389671
- Locations
- 🇺🇸
Augusta University Health, Augusta, Georgia, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇦🇷Hospital Alemán, Buenos Aires, Argentina
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT04325035
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇦🇷Hospital Italiano de Bueno Aires, Capital Federal, Buenos Aires, Argentina
🇦🇷Santorio Guemes, Capital Federal, Buenos Aires, Argentina
A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age
- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- Combination Product: Lucinactant for InhalationOther: nCPAP Only
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT04264156
- Locations
- 🇵🇱
Ginekologiczno-Polozniczy Szpital Kliniczny Uniwewersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland
🇵🇱Samodzielny Publiczny Spcjalistyczny Zaklad Opieki Zdrowotnej "Zdroje", Oddzial Noworodkow, Szczecin, Poland
🇵🇱Szpital Specjalistyczny nr 2 w Bytomiu Oddzial Noworodkow Blok Va, Bytom, Poland
Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 240
- Registration Number
- NCT03217825
- Locations
- 🇨🇳
Cvie Therapeutics Limited, Taipei, Taiwan
The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
- Conditions
- Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 221
- Registration Number
- NCT02636868
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Univ. of Arkansas Medical Center, Little Rock, Arkansas, United States
🇺🇸Case Western Reserve University (Rainbow Babies Hosp.), Cleveland, Ohio, United States
The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT02617446
- Locations
- 🇮🇹
University of Milano-Bicocca, Milan, Italy
🇮🇹University and Civil Hospital of Brescia, Brescia, Italy
🇨🇳Lanzhou University No.2 Hospital, Lanzhou, Gansu, China
Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Combination Product: Lucinactant for inhalationDevice: nCPAP alone
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT02528318
- Locations
- 🇨🇱
Hospital Dr Sotero Del Rio, Santiago, Chile
🇨🇱Hospital San Juan de Dios, Santiago, Chile
🇵🇱Instytut Centrum Zdrowja Matki Polki Klinika Neonatologii, Lodz, Lodzkie, Poland
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Device: nCPAP alone
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT02074059
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States
Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 17
- Registration Number
- NCT00807235
- Locations
- 🇺🇸
University of California, San Diego Medical Center - Hillcrest, San Diego, California, United States